On December 9, 2024, Legend Biotech Corp announced significant data showing high rates of minimal residual disease (MRD)-negativity in patients treated with CARVYKTI® during the Phase 3 CARTITUDE-4 trial for multiple myeloma. These findings were presented at the 66th ASH Annual Meeting in San Diego.